About
Menten AI
Menten AI is pioneering generative AI to design cyclic peptide therapeutics for drug targets beyond the reach of small molecules and biologics. Our proprietary platform, MAUD 1.0, enables the rapid creation of macrocycles with drug-like properties such as oral bioavailability and cell permeability.
We partner with top-10 pharma leaders (e.g., Bristol Myers Squibb) to accelerate preclinical discovery, and we are backed by world-class investors including Social Impact Capital, Uncork Capital, Khosla Ventures, and Y Combinator.
MAUD 1.0
MAUD 1.0 (Multi-parametric AI for Unbiased Design) integrates generative AI, physics-based modeling, and quantum chemistry simulations to design novel peptide macrocycles from scratch—bypassing the limitations of traditional library screening.
Unlike traditional machine learning approaches, MAUD 1.0 leverages physics-informed generative AI, eliminating the need for large training datasets while enabling efficient peptide design with atomic precision.
Its multi-parametetric approach optimizes multiple properties simultaneously (e.g. potency, permeability, stability), creating a shortcut to the right chemical space and enabling faster, more effective therapeutic discovery.
Validation
MAUD 1.0 has been validated across the preclinical pipeline—from in silico design to in vitro and in vivo studies - demonstrating:
- nM-level potency
- Membrane permeability
- Favorable DMPK properties
- In vivo efficacy
%201.svg){kind=icon}
.webp)
